StockNews.com Downgrades Atrion (NASDAQ:ATRI) to Sell

Atrion (NASDAQ:ATRI) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Atrion Price Performance

NASDAQ:ATRI opened at $471.99 on Tuesday. Atrion has a one year low of $274.98 and a one year high of $602.59. The business has a fifty day moving average price of $427.41 and a 200-day moving average price of $375.64. The firm has a market capitalization of $830.70 million, a price-to-earnings ratio of 44.36 and a beta of 0.62.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The business had revenue of $47.33 million during the quarter.

Hedge Funds Weigh In On Atrion

Several institutional investors have recently bought and sold shares of ATRI. Citizens Financial Group Inc. RI purchased a new stake in shares of Atrion in the fourth quarter valued at $1,114,000. Charles Schwab Investment Management Inc. boosted its holdings in Atrion by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock valued at $4,291,000 after acquiring an additional 243 shares during the period. Tower Research Capital LLC TRC grew its position in Atrion by 592.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 231 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Atrion by 2.0% in the third quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock worth $4,134,000 after purchasing an additional 194 shares during the period. Finally, WINTON GROUP Ltd bought a new stake in shares of Atrion during the third quarter worth $208,000. 66.19% of the stock is owned by hedge funds and other institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.